RPL17 and neoplasm: By employing ICI mAbs to stop the interaction between PD-1 and its ligands (PD-L1 and PD-L2), the PD-1/PD-L1-induced immunosuppression was reversed, this in turn, revived the cytotoxic functions of CTLs against tumor antigens, leading to inhibition of neoplastic growth [8].